World fibromyalgia syndrome market to grow at a CAGR of 9.2% for the next seven years, reaching $1.8 billion by 2015, forecasts Global Data
The global market for fibromyalgia syndrome (FMS) drugs was valued at some $1 billion in 2008 and is estimated to grow at a Compound Annual Growth Rate (CAGR) of 9.2% for the next seven years to reach $1.8 billion by 2015, according to a new report from GlobalData.
The growth will be driven by several factors such as escalation in FMS prevalence and the high level of unmet needs prevailing in the sector. Barriers for the FMS sector are inadequate knowledge of the disease and limited effectiveness of existing drugs which moderately affect the growth of the market. The moderate treatment-seeking and low diagnosis rate also act as a barrier to market volume in the sector, the report notes.
Market remains imperceptibly competitive
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze